ArticlemAbs2026
Population-level analysis of glycoprotein glycoforms.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The structure and function of many proteins are regulated post-translationally through glycan attachment. These glycans, assembled via competing enzymatic reactions, generate diverse glycoform populations - variants sharing a protein backbone but differing in glycan structures. While current analyses often focus on individual glycoforms, we demonstrate that population-level glycoform analysis - integrating spectral, biosynthetic, and physicochemical relationships - reveals new insights into glycoprotein regulation. Applied to immunoglobulin subclasses and antithrombin III (AT3), this approach provides comprehensive coverage of glycoform repertoires from human and murine plasma and biopharmaceuticals. It also enables sensitive quantification of glycosylation changes arising from in vitro manipulations or in vivo infections. Finally, we introduce a statistical framework adapted from ecological biodiversity studies, revealing that both IgG and AT3 exhibit skewed glycoform distributions shaped by biosynthetic constraints and degradation. Our findings demonstrate the added value of population-level glycoform analysis in understanding protein function and regulation through glycosylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.